Bladder cancer patients get new hope from Immuno-Radiation combo

This early-stage trial tests the safety of combining the immunotherapy drug pembrolizumab with radiation therapy for people with advanced bladder cancer. About 34 patients with either locally advanced or metastatic disease will receive pembrolizumab before and during radiation, then continue the drug for up to a year. The study aims to find the best dose and see how well the combination controls the cancer.